Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACAD NASDAQ:EWTX NASDAQ:ORIC NASDAQ:VKTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACADACADIA Pharmaceuticals$24.84+0.0%$23.23$19.69▼$28.35$4.25B0.81.73 million shs1.05 million shsEWTXEdgewise Therapeutics$40.84+3.9%$37.68$12.30▼$48.40$4.23B0.271.11 million shs1.03 million shsORICOric Pharmaceuticals$12.10+11.1%$9.39$7.23▼$14.93$1.13B1.021.57 million shs3.61 million shsVKTXViking Therapeutics$34.79-1.7%$33.79$22.96▼$43.15$4.11B0.662.27 million shs1.84 million shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACADACADIA Pharmaceuticals-0.52%-3.12%+9.87%+13.07%+6.70%EWTXEdgewise Therapeutics+2.50%+2.88%+1.18%+24.41%+173.04%ORICOric Pharmaceuticals+1.30%+1.49%+22.22%+6.35%-7.71%VKTXViking Therapeutics-5.15%-2.69%+1.67%+8.06%+5.96%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACADACADIA Pharmaceuticals$24.84+0.0%$23.23$19.69▼$28.35$4.25B0.81.73 million shs1.05 million shsEWTXEdgewise Therapeutics$40.84+3.9%$37.68$12.30▼$48.40$4.23B0.271.11 million shs1.03 million shsORICOric Pharmaceuticals$12.10+11.1%$9.39$7.23▼$14.93$1.13B1.021.57 million shs3.61 million shsVKTXViking Therapeutics$34.79-1.7%$33.79$22.96▼$43.15$4.11B0.662.27 million shs1.84 million shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACADACADIA Pharmaceuticals-0.52%-3.12%+9.87%+13.07%+6.70%EWTXEdgewise Therapeutics+2.50%+2.88%+1.18%+24.41%+173.04%ORICOric Pharmaceuticals+1.30%+1.49%+22.22%+6.35%-7.71%VKTXViking Therapeutics-5.15%-2.69%+1.67%+8.06%+5.96%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACADACADIA Pharmaceuticals 2.67Moderate Buy$33.1733.52% UpsideEWTXEdgewise Therapeutics 2.82Moderate Buy$48.7519.37% UpsideORICOric Pharmaceuticals 2.75Moderate Buy$19.2759.28% UpsideVKTXViking Therapeutics 2.67Moderate Buy$97.00178.82% UpsideCurrent Analyst Ratings BreakdownLatest ORIC, ACAD, VKTX, and EWTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/21/2026ACADACADIA Pharmaceuticals BMO Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$34.00 ➝ $36.007/21/2026ACADACADIA Pharmaceuticals Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetHold$24.00 ➝ $25.007/20/2026EWTXEdgewise Therapeutics EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$55.007/20/2026VKTXViking Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell7/17/2026EWTXEdgewise Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/17/2026ORICOric Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/17/2026VKTXViking Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/9/2026EWTXEdgewise Therapeutics OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$51.007/7/2026ACADACADIA Pharmaceuticals Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$29.00 ➝ $36.007/6/2026EWTXEdgewise Therapeutics GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$41.00 ➝ $51.006/30/2026ACADACADIA Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold(Data available from 7/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACADACADIA Pharmaceuticals$1.07B3.97$0.89 per share27.99$7.25 per share3.43EWTXEdgewise TherapeuticsN/AN/AN/AN/A$4.93 per shareN/AORICOric PharmaceuticalsN/AN/AN/AN/A$3.90 per shareN/AVKTXViking TherapeuticsN/AN/AN/AN/A$5.65 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACADACADIA Pharmaceuticals$391M$2.2011.2925.8817.2234.30%9.61%7.07%8/4/2026 (Confirmed)EWTXEdgewise Therapeutics-$167.79M-$1.66N/AN/AN/AN/A-32.55%-31.04%8/6/2026 (Estimated)ORICOric Pharmaceuticals-$129.47M-$1.44N/AN/AN/AN/A-35.33%-33.31%8/11/2026 (Estimated)VKTXViking Therapeutics-$359.64M-$4.14N/AN/AN/AN/A-71.31%-65.35%7/29/2026 (Estimated)Latest ORIC, ACAD, VKTX, and EWTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2026Q2 2026ORICOric Pharmaceuticals-$0.36N/AN/AN/AN/AN/A8/6/2026Q2 2026EWTXEdgewise Therapeutics-$0.48N/AN/AN/AN/AN/A8/4/2026Q2 2026ACADACADIA Pharmaceuticals$0.06N/AN/AN/A$295.51 millionN/A7/29/2026Q2 2026VKTXViking Therapeutics-$1.21N/AN/AN/AN/AN/A5/7/2026Q1 2026EWTXEdgewise Therapeutics-$0.50-$0.46+$0.04-$0.46N/AN/A5/6/2026Q1 2026ACADACADIA Pharmaceuticals$0.04$0.02-$0.02$0.02$280.25 million$268.10 million5/4/2026Q1 2026ORICOric Pharmaceuticals-$0.31-$0.34-$0.03-$0.34N/AN/A4/30/2026Q1 2026VKTXViking Therapeutics-$1.01-$1.37-$0.36-$1.37N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthACADACADIA PharmaceuticalsN/AN/AN/AN/AN/AEWTXEdgewise TherapeuticsN/AN/AN/AN/AN/AORICOric PharmaceuticalsN/AN/AN/AN/AN/AVKTXViking TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACADACADIA PharmaceuticalsN/A3.593.48EWTXEdgewise TherapeuticsN/A22.6122.61ORICOric PharmaceuticalsN/A16.3316.33VKTXViking TherapeuticsN/A5.725.72Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACADACADIA Pharmaceuticals96.71%EWTXEdgewise TherapeuticsN/AORICOric Pharmaceuticals95.05%VKTXViking Therapeutics76.03%Insider OwnershipCompanyInsider OwnershipACADACADIA Pharmaceuticals26.20%EWTXEdgewise Therapeutics21.30%ORICOric Pharmaceuticals5.70%VKTXViking Therapeutics5.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACADACADIA Pharmaceuticals510171.24 million126.37 millionOptionableEWTXEdgewise Therapeutics60107.59 million84.68 millionOptionableORICOric Pharmaceuticals80103.52 million97.62 millionOptionableVKTXViking Therapeutics20116.11 million109.95 millionOptionableORIC, ACAD, VKTX, and EWTX HeadlinesRecent News About These CompaniesHere's Why Viking Therapeutics, Inc. (VKTX) Fell More Than Broader MarketJuly 23 at 10:54 PM | finance.yahoo.comViking Therapeutics (VKTX) Appoints Dorothy Gemmell To Board As Commercial Focus Comes Into ViewJuly 23 at 10:54 PM | finance.yahoo.comViking Therapeutics (VKTX) Stock Could Be Overvalued On Fresh Diabetes Therapy NewsJuly 23 at 10:54 PM | finance.yahoo.comHere's Why Viking Therapeutics, Inc. (VKTX) Fell More Than Broader MarketJuly 23 at 6:46 PM | zacks.comViking Therapeutics Appoints Dorothy Gemmell to Board of DirectorsJuly 23 at 7:52 AM | finance.yahoo.comViking Therapeutics Appoints Dorothy Gemmell to Board of DirectorsJuly 23 at 7:05 AM | prnewswire.comViking Therapeutics to Report Financial Results for Second Quarter 2026 on July 29, 2026July 22 at 7:58 PM | finance.yahoo.comViking Therapeutics to Report Financial Results for Second Quarter 2026 on July 29, 2026July 22 at 4:05 PM | prnewswire.comViking Therapeutics (NASDAQ:VKTX) Rating Lowered to "Strong Sell" at Zacks ResearchJuly 22 at 5:41 AM | marketbeat.comViking Therapeutics (VKTX) to Release Earnings on WednesdayJuly 22 at 4:40 AM | marketbeat.comViking Therapeutics (NASDAQ:VKTX) Stock Crosses Above 50 Day Moving Average - Here's What HappenedJuly 22 at 4:19 AM | marketbeat.comKuehn Law Encourages Investors of Viking Therapeutics, Inc. to Contact Law FirmJuly 21 at 4:41 PM | prnewswire.comHead-To-Head Analysis: Capstone Therapeutics (NASDAQ:CAPS) vs. Viking Therapeutics (NASDAQ:VKTX)July 21 at 3:49 AM | americanbankingnews.comWatch Out, Eli Lilly and Novo Nordisk: Viking Therapeutics Just Started Testing a Weight Loss Drug That Goes Beyond GLP-1July 18, 2026 | fool.comShould You Buy Viking Therapeutics Stock on the Dip? Wall Street Is Screaming "Yes.July 18, 2026 | fool.comViking Therapeutics, Inc. (VKTX) Ascends While Market Falls: Some Facts to NoteJuly 17, 2026 | finance.yahoo.comViking Therapeutics, Inc. (VKTX) Ascends While Market Falls: Some Facts to NoteJuly 17, 2026 | zacks.comViking Therapeutics to Report Q2 Earnings: What's in Store for the Stock?July 17, 2026 | finance.yahoo.comViking Therapeutics to Report Q2 Earnings: What's in Store for the Stock?July 17, 2026 | zacks.comThe weight-loss drugs boom is creating both winners and wipeouts: One Big Investment IdeaJuly 17, 2026 | finance.yahoo.comKuehn Law Encourages Investors of Viking Therapeutics, Inc. to Contact Law FirmJuly 16, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSK Hynix’s Nasdaq Listing Could Reset the AI Memory TradeBy Thomas Hughes | July 7, 20265 Tech Stocks to Buy on the July PullbackBy Thomas Hughes | June 29, 2026Rocket Lab’s Stock Drop Comes With a Bullish TwistBy Ryan Hasson | July 10, 2026AirJoule Unveils Prime System, Clearing Path to CommercializationBy Thomas Hughes | July 1, 2026PepsiCo’s Dividend Could Turn Patience Into Real ProfitBy Thomas Hughes | July 10, 2026ORIC, ACAD, VKTX, and EWTX Company DescriptionsACADIA Pharmaceuticals NASDAQ:ACAD$24.84 +0.01 (+0.04%) Closing price 04:00 PM EasternExtended Trading$24.84 0.00 (0.00%) As of 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.Edgewise Therapeutics NASDAQ:EWTX$40.84 +1.55 (+3.95%) Closing price 04:00 PM EasternExtended Trading$41.30 +0.45 (+1.11%) As of 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.Oric Pharmaceuticals NASDAQ:ORIC$12.10 +1.21 (+11.11%) Closing price 04:00 PM EasternExtended Trading$12.14 +0.04 (+0.29%) As of 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers. It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.Viking Therapeutics NASDAQ:VKTX$34.79 -0.60 (-1.70%) Closing price 04:00 PM EasternExtended Trading$35.06 +0.27 (+0.76%) As of 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AMD and Cerbras Create A New Blueprint For Hardware Intel Earnings Reveal Whether the Chip Selloff Created a Buy CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test Freeport McMoRan Post-Earnings: Why Good Enough May Finally Be Good Enough Tesla Just Delivered Record Sales—So Why Did the Stock Sell Off? Plugging In: How Kinder Morgan Powers Up Profits TSMC’s Price Hikes Could Show Which AI Chip Stocks Have Real Pricing Power AMD’s $5 Billion Anthropic Deal Could Redraw the AI Chip Battle Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
